Mallinckrodt PLC (NYSE:MNK) shares traded down 0.9% on Tuesday . The company traded as low as $61.53 and last traded at $61.94, with a volume of 1,139,110 shares changing hands. The stock had previously closed at $62.52.

A number of research analysts recently weighed in on the stock. Morgan Stanley reissued a “buy” rating on shares of Mallinckrodt PLC in a research report on Wednesday, April 27th. Goldman Sachs Group Inc. assumed coverage on shares of Mallinckrodt PLC in a research report on Monday, June 6th. They set a “neutral” rating and a $73.00 price target on the stock. Mizuho reissued a “buy” rating on shares of Mallinckrodt PLC in a research report on Monday, June 6th. Vetr lowered shares of Mallinckrodt PLC from a “buy” rating to a “sell” rating and set a $61.84 price target on the stock. in a research report on Monday, June 6th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating and set a $85.00 price target (down from $100.00) on shares of Mallinckrodt PLC in a research report on Wednesday, May 4th. Four research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $91.13.

The company’s 50-day moving average is $60.67 and its 200 day moving average is $62.81. The stock has a market capitalization of $6.77 billion and a P/E ratio of 15.53.

Mallinckrodt PLC (NYSE:MNK) last posted its earnings results on Tuesday, May 3rd. The company reported $2.01 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.72 by $0.29. During the same quarter in the prior year, the company posted $1.72 EPS. The company had revenue of $918 million for the quarter, compared to the consensus estimate of $878.70 million. Mallinckrodt PLC’s revenue was up 12.1% on a year-over-year basis. Equities analysts forecast that Mallinckrodt PLC will post $8.28 EPS for the current year.

In related news, VP Hugh M. O’neill bought 1,653 shares of the stock in a transaction on Tuesday, May 10th. The shares were acquired at an average price of $60.99 per share, for a total transaction of $100,816.47. Following the purchase, the vice president now owns 15,623 shares of the company’s stock, valued at $952,846.77. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Steven J. Romano bought 900 shares of the stock in a transaction on Friday, May 6th. The shares were bought at an average price of $56.00 per share, for a total transaction of $50,400.00. Following the purchase, the vice president now directly owns 9,291 shares in the company, valued at approximately $520,296. The disclosure for this purchase can be found here.

A number of institutional investors recently bought and sold shares of MNK. Gamco Investors INC. ET AL bought a new position in Mallinckrodt PLC during the fourth quarter valued at about $1,161,000. Markston International LLC boosted its position in Mallinckrodt PLC by 38.0% in the fourth quarter. Markston International LLC now owns 16,693 shares of the company’s stock valued at $1,246,000 after buying an additional 4,593 shares in the last quarter. Commerzbank Aktiengesellschaft FI boosted its position in Mallinckrodt PLC by 93.9% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 17,458 shares of the company’s stock valued at $1,303,000 after buying an additional 8,456 shares in the last quarter. Suntrust Banks Inc. boosted its position in Mallinckrodt PLC by 9.4% in the fourth quarter. Suntrust Banks Inc. now owns 29,987 shares of the company’s stock valued at $2,236,000 after buying an additional 2,574 shares in the last quarter. Finally, Nationwide Fund Advisors boosted its position in Mallinckrodt PLC by 1.8% in the fourth quarter. Nationwide Fund Advisors now owns 34,985 shares of the company’s stock valued at $2,611,000 after buying an additional 606 shares in the last quarter.

Mallinckrodt public limited company (Mallinckrodt) is engaged in the specialty pharmaceuticals and nuclear imaging business. The Company develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products, and nuclear imaging agents. The Company’s segments include Specialty Brands, Specialty Generics and Nuclear Imaging.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.